Memoria del Derecho y disciplinas jurídicas. Estudios

This work collects the presentations made at the III International Seminar Memory of Law and Legal Disciplines (XIX-XX centuries) held on May 25 and 26, 2022 at the Santa María de la Rábida Campus of the International University of Andalusia, in Palos de la Frontera, Huelva. The following pages discuss the lives of legal scholars as well as the emergence of legal disciplines and legal education in Spain in the period spanning from the Moyano Law of Public Instruction (1857) to the University Reform Law (1983).PublishedEsta es una obra colectiva que recoge las contribuciones realizadas en el III Seminario Internacional Memoria del derecho y disciplinas jurídicas (siglos XIX-XX) celebrado los días 25 y 26 de mayo de 2022 en la Sede de Santa María de la Rábida de la Universidad Internacional de Andalucía, en Palos de la Frontera, Huelva. En estas páginas se da cuenta de la memoria del jurista, así como de la formación de las disciplinas y enseñanzas jurídicas, durante el largo período que va de la Ley Moyano de Instrucción Pública (1857) hasta Ley de Reforma Universitaria (1983)

Derecho ex cathedra. 1847-1936 Diccionario de catedráticos españoles

Edición revisada 2020.Publicación de las entradas biográficas del Diccionario de catedráticos españoles de Derecho, accesible en http://www.uc3m.es/diccionariodecatedraticos. Al dar forma de libro al material hemos prescindido de algunos elementos informativos, que se mantienen en la página electrónica indicada. Se recogen ahora solamente a los ingresados en el cuerpo con anterioridad a la guerra civil.Publication of the biographical entries of the Diccionario de catedráticos españoles de Derecho, accessible at http://www.uc3m.es/diccionariodecatedraticos. By giving those material book form, we have dispensed with some informative elements, however kept on the web page. Only professors apointed prior to the Civil War are now included.Esta publicación forma parte del proyecto “La memoria del jurista español: génesis y desarrollo de las disciplinas jurídicas” (ref. DER2014-55035-C2-1-P/DER2014-55035-C2-2-P), financiado por el Ministerio de Economía, Industria y Competitividad (España)

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Jornada d'homenatge al professor de la Facultat de Dret Manuel Cachón Cadenas

Gravació de la Jornada d’homenatge al professor Manuel Cachón Cadenas, que va tenir lloc el divendres 10 de maig de 2024, a les 11 hores, a l’Aula Magna de la Facultat de Dret. El programa va ser el següent: 11.00-11.15h “Inauguració” a càrrec de la Dra. Esther Zapater Duque, Secretaria General de la Universitat Autònoma de Barcelona, i el Dr. Josep Maria de Dios Marcer, Director del Departament de Dret Privat ; 11.15-12:15h “Taula 1. Les històries del Professor Cachón”: "La història del procés" a càrrec del Dr. Joan Picó Junoy, Catedràtic de Dret Processal, "El Professor Cachón historiador" a càrrec del Dr. José Juan Moreso Mateos, Catedràtic de Filosofia del Dret, i "La història del Professor Cachón", a càrrec del Dr. Enric Fossas Espadaler, Catedràtic de Dret Constitucional. Moderadora: Dra. Cristina Riba Trepat, Professora Titular de Dret Processal ; 12.15-14:00h “Taula 2. Ciència processal i l' obra del Professor Cachón”: "El desconcertant règim de tutela col·lectiva en el procés civil espanyol. A l'espera de decisions prejudicials del TJUE" a càrrec del Dr. Manuel Ortells Ramos, Catedràtic de Dret Processal, "Propostes per a la millora de l' eficàcia del procés d' execució" a càrrec del Dr. Vicente Pérez Daudí, Catedràtic de Dret Processal, i "Aproximació a l' obra del Professor Cachón" a càrrec del Dr. Francisco Ramos Romeu, Professor Titular de Dret Processal. Moderador: Dr. Just Franco Arias, Catedràtic de Dret Processal ; 17:00-19:30h “Taula 3. El pas del Professor Cachón per la universitat” a càrrec del Dr. Francisco Ramos Méndez, Catedràtic de Dret Processal, Dra. Victoria Berzosa Francos, Professora Titular de Dret Processal, Dr. Just Franco Arias, Catedràtic de Dret Processal, Dr. Josep Cid Moliné, Catedràtic de Dret Penal, Dr. Carlos Petit Calvo, Catedràtic d' Història del Dret, Sr. Juan Alarcón Gutiérrez, Advocat i Professor Associat de Dret Processal, Dr. Mario Zopellari, Advocat i Professor de Dret Processal, Dr. Manuel Férez Fernández, Professor Titular de Dret Administratiu i Dra. Carmen Navarro Villanueva, Professora Titular de Dret Processal. Moderadora: Dra. Susana Navas Navarro, Catedràtica de Dret Civil i Degana de la Facultat de Dret ; 19:30-20h “Clausura” a càrrec de Susana Navas Navarro, Degana de la Facultat de Dret

Delayed colorectal cancer care during covid-19 pandemic (decor-19). Global perspective from an international survey

Background The widespread nature of coronavirus disease 2019 (COVID-19) has been unprecedented. We sought to analyze its global impact with a survey on colorectal cancer (CRC) care during the pandemic. Methods The impact of COVID-19 on preoperative assessment, elective surgery, and postoperative management of CRC patients was explored by a 35-item survey, which was distributed worldwide to members of surgical societies with an interest in CRC care. Respondents were divided into two comparator groups: 1) ‘delay’ group: CRC care affected by the pandemic; 2) ‘no delay’ group: unaltered CRC practice. Results A total of 1,051 respondents from 84 countries completed the survey. No substantial differences in demographics were found between the ‘delay’ (745, 70.9%) and ‘no delay’ (306, 29.1%) groups. Suspension of multidisciplinary team meetings, staff members quarantined or relocated to COVID-19 units, units fully dedicated to COVID-19 care, personal protective equipment not readily available were factors significantly associated to delays in endoscopy, radiology, surgery, histopathology and prolonged chemoradiation therapy-to-surgery intervals. In the ‘delay’ group, 48.9% of respondents reported a change in the initial surgical plan and 26.3% reported a shift from elective to urgent operations. Recovery of CRC care was associated with the status of the outbreak. Practicing in COVID-free units, no change in operative slots and staff members not relocated to COVID-19 units were statistically associated with unaltered CRC care in the ‘no delay’ group, while the geographical distribution was not. Conclusions Global changes in diagnostic and therapeutic CRC practices were evident. Changes were associated with differences in health-care delivery systems, hospital’s preparedness, resources availability, and local COVID-19 prevalence rather than geographical factors. Strategic planning is required to optimize CRC care